Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.

@article{Massoudi2017NumberNT,
  title={Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-na{\"i}ve patients with metastatic castration-resistant prostate cancer.},
  author={Marjan Massoudi and Mark R. Montgomery Deborah Balk and Hongbo Yang and Cat N. Bui and Bhavik J Pandya and Jenny Guo and Yan Song and Eric Qiong Wu and Bruce J Brown and Arie Barlev and Scott C. Flanders},
  journal={Journal of medical economics},
  year={2017},
  volume={20 2},
  pages={121-128}
}
OBJECTIVE Enzalutamide (ENZA) and abiraterone acetate plus prednisone (AA) are approved second-generation hormone therapies for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). This study compared ENZA with AA in chemotherapy-naïve mCRPC by calculating the number needed to treat (NNT) and associated incremental costs to achieve one additional chemotherapy-naïve patient with mCRPC free of radiographic progression, chemotherapy, or death over a 1-year time horizon… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS